María Victoria
Mateos Manteca
Profesora Titular de Universidad
Charles University in Prague
Praga, República ChecaCharles University in Prague-ko ikertzaileekin lankidetzan egindako argitalpenak (28)
2024
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
Haematologica, Vol. 109, Núm. 3, pp. 867-876
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica, Vol. 109, Núm. 3, pp. 895-905
-
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Haematologica
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Blood, Vol. 141, Núm. 6, pp. 579-591
-
Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1600-1609
-
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 5, pp. 1172-1177
2022
-
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
Haematologica, Vol. 107, Núm. 10, pp. 2408-2417
-
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110
2021
-
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718
-
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Journal of Hematology and Oncology
-
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
British Journal of Haematology, Vol. 193, Núm. 3, pp. 561-569
-
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130
2020
-
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509
-
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
-
Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial
Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 4030-4041
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
-
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
The Lancet Haematology, Vol. 7, Núm. 5, pp. e370-e380
2019
-
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Annals of Hematology, Vol. 98, Núm. 9, pp. 2139-2150